{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:02:40Z","timestamp":1789509760602,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102641","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:06:08Z","timestamp":1785996368000},"page":"102641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Outcomes Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Gu\u00e9rin: A SEER-Medicare Analysis"],"prefix":"10.1016","author":[{"given":"Yair","family":"Lotan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8956-1725","authenticated-orcid":false,"given":"Shujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3547-8548","authenticated-orcid":false,"given":"Sandy S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7030-6780","authenticated-orcid":false,"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-2813","authenticated-orcid":false,"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pangsibo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102641_bib0001","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. 2025; https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html (Retrieved August 20, 2025)."},{"key":"10.1016\/j.clgc.2026.102641_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102641_bib0003","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102641_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101843","article-title":"Treatment modalities for non-muscle invasive bladder cancer: an updated review","volume":"16","author":"McNall","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.clgc.2026.102641_bib0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Fut Oncol"},{"key":"10.1016\/j.clgc.2026.102641_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEOR.S341896","article-title":"Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR)","volume":"14","author":"Musat","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.clgc.2026.102641_bib0007","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/BLC-230047","article-title":"Comparative analysis of very reduced vs full dose BCG treatment for high-risk non-muscle invasive bladder cancer: a contemporary experience from Chile","volume":"9","author":"Grajales","year":"2023","journal-title":"Bladder Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2026.102641_bib0008","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102641_bib0009","first-page":"1","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2026.102641_bib0010","unstructured":"Healthcare Delivery Research Program SEER-Medicare: Medicare claims data linked to SEER cancer registries. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/ (Retrieved August 20, 2025)."},{"issue":"5","key":"10.1016\/j.clgc.2026.102641_bib0011","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/bju.14529","article-title":"Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of surveillance, epidemiology and end results-Medicare data","volume":"123","author":"Lane","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.clgc.2026.102641_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102641_bib0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.euo.2018.03.005","article-title":"Systematic review of comorbidity and competing-risks assessments for bladder cancer patients","volume":"1","author":"Williams","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102641_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.4601","article-title":"Assessing real-world recurrence in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) treated with bacillus Calmette-Gu\u00e9rin (BCG) in the United States through a recurrence algorithm: a SEER-Medicare study","volume":"43","author":"Lotan","year":"2025","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.clgc.2026.102641_bib0016","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euf.2025.04.033","article-title":"Long-term oncological outcomes for patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG): a comparative analysis of adequate versus inadequate BCG treatment","volume":"12","author":"Scilipoti","year":"2026","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.clgc.2026.102641_bib0017","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2025.12.022","article-title":"Efficacy and safety of checkpoint inhibitors combined with Bacillus Calmette-Guerin (BCG) in BCG-naive high-risk non-muscle-invasive bladder cancer: synthesis of evidence from the ALBAN, CREST, and POTOMAC trials","volume":"89","author":"Scilipoti","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102641_bib0018","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"issue":"10","key":"10.1016\/j.clgc.2026.102641_bib0019","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.clgc.2026.102641_bib0020","doi-asserted-by":"crossref","first-page":"456.e413","DOI":"10.1016\/j.urolonc.2023.08.003","article-title":"Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy","volume":"41","author":"Moon","year":"2023","journal-title":"Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:07:38Z","timestamp":1789506458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"alternative-id":["S1558767326001412"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102641","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Clinical Outcomes Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Gu\u00e9rin: A SEER-Medicare Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102641"}}